Edwards slips as Sapien forecast disappoints
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences’ share price dipped 5% on 9 December after it put out lower-than-expected sales guidance for its transcatheter heart valves, as it faces competition from rival Medtronic. The firm said during an investor conference that it is now expecting global revenues from these devices to total $700-820m, below analyst consensus of $844.7m.